Long-term effect of letrozole on metastatic uterine smooth muscle tumors of uncertain malignant potential: A case report

J Obstet Gynaecol Res. 2023 Nov;49(11):2771-2776. doi: 10.1111/jog.15777. Epub 2023 Aug 23.

Abstract

A 48-year-old woman underwent total abdominal hysterectomy and right salpingo-oophorectomy and was initially diagnosed with a uterine leiomyoma and right ovarian cystadenoma. After 4 years, multiple pulmonary metastases were identified, and treatment with gonadotropin-releasing hormone agonists was started, but stopped later due to disease progression. The patient developed dyspnea and underwent right upper lobectomy. The histopathological findings were consistent with those of pulmonary metastases secondary to a uterine smooth muscle tumor of uncertain malignant potential. Slow disease progression after a poor response to adriamycin and hormone receptor positivity led to the start of letrozole. Letrozole induced spontaneous regression of the pulmonary metastases, and about 2 years into the treatment, sustained response was achieved with minimal side effects. This may be the first case supporting the long-term efficacy and safety of letrozole in the management of adriamycin-resistant lung metastases of uterine smooth muscle tumors of uncertain malignant potential.

Keywords: gynecology; leiomyoma; letrozole; metastasis; smooth muscle tumor.

Publication types

  • Case Reports

MeSH terms

  • Disease Progression
  • Doxorubicin
  • Female
  • Humans
  • Letrozole
  • Lung Neoplasms* / pathology
  • Middle Aged
  • Smooth Muscle Tumor* / drug therapy
  • Smooth Muscle Tumor* / pathology
  • Smooth Muscle Tumor* / surgery
  • Uterine Neoplasms* / surgery

Substances

  • Letrozole
  • Doxorubicin